By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


VBL Therapeutics 

6 Jonathan Netanyahu Street

Or Yehuda    60376  Israel
Phone: 97-236-346450 Fax: 97-236-346449



Company News
VBL Therapeutics (VBLX) Provides Update On Long-Term Survival In Phase II Trials Of Patients With Multiple Tumor Types 6/19/2017 10:59:18 AM
VBL Therapeutics (VBLX) Announces Appointment Of Dr. Corinne Epperly As U.S. Chief Operating Officer 6/15/2017 11:09:04 AM
VBL Therapeutics (VBLX) Awarded $2.5 Million Grant By The Israel Innovation Authority 6/8/2017 10:54:35 AM
VBL Therapeutics (VBLX) Announces First Quarter 2017 Financial Results 5/15/2017 8:29:47 AM
VBL Therapeutics (VBLX) Presents Data On VB-111 In Combination With Checkpoint Inhibitor At The 20th Annual ASGCT Meeting 5/11/2017 11:18:44 AM
VBL Therapeutics (VBLX) To Report First Quarter 2017 Results On May 15 5/3/2017 9:56:19 AM
VBL Therapeutics (VBLX) Announces Positive DSMC Review in Phase III GLOBE Trial Investigating VB-111 in rGBM 4/21/2017 11:09:13 AM
VBL Therapeutics (VBLX) Announces Second Quarter 2016 Financial Results And Provides Business Update 8/15/2016 11:57:52 AM
ASCO2016: VBL Therapeutics (VBLX) VB-111 Clinical Data Presented At ASCO Demonstrate Significant Increase In Overall Survival In Platinum-Resistant Ovarian Cancer 6/6/2016 3:49:08 PM
Newly Granted U.S. Composition Of Matter Patent Extends Exclusive Protection For VBL Therapeutics (VBLX)' Lead Drug Candidate VB-111 Until October 2033 12/1/2015 7:29:44 AM